Zhitong Financial App News, Hanson Pharmaceuticals (03692.HK) issued an announcement. On September 29, 2026, the Group re-submitted a marketing license application (MAA) for the innovative drug ametinib in the European Union (EMA), and on October 7, 2026, the EMA confirmed acceptance of the new MAA and officially initiated a centralized approval process. The indications are: (i) advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 missing or exon 21 (L858R) replacement mutations (NSCLC) adult patients First-line treatment, and (ii) treatment of adult patients with advanced NSCLC who are positive for the EGFR T790M mutation.

Zhitongcaijing · 1d ago
Zhitong Financial App News, Hanson Pharmaceuticals (03692.HK) issued an announcement. On September 29, 2026, the Group re-submitted a marketing license application (MAA) for the innovative drug ametinib in the European Union (EMA), and on October 7, 2026, the EMA confirmed acceptance of the new MAA and officially initiated a centralized approval process. The indications are: (i) advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 missing or exon 21 (L858R) replacement mutations (NSCLC) adult patients First-line treatment, and (ii) treatment of adult patients with advanced NSCLC who are positive for the EGFR T790M mutation.